Innoviva Inc (INVA) - Total Liabilities
Based on the latest financial reports, Innoviva Inc (INVA) has total liabilities worth $469.46 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Innoviva Inc (INVA) investment intensity to see how much of total assets are deployed in long-term investments.
Innoviva Inc - Total Liabilities Trend (2000–2025)
This chart illustrates how Innoviva Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see how large is Innoviva Inc's balance sheet.
Innoviva Inc Competitors by Total Liabilities
The table below lists competitors of Innoviva Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Latigo Biotherapeutics, Inc. Common Stock
NASDAQ:LTGO
|
USA | $340.84 Million |
|
OliX PharmaceuticalsInc
KQ:226950
|
Korea | ₩40.96 Billion |
|
IGNITIS GRUPE AB EO 2233
F:IGV0
|
Germany | €3.78 Billion |
|
Nanjing Vazyme Biotech Co Ltd
SHG:688105
|
China | CN¥1.03 Billion |
|
Fujian Snowman Co Ltd
SHE:002639
|
China | CN¥2.43 Billion |
|
Companhia Siderúrgica Nacional
MX:SIDN
|
Mexico | MX$83.47 Billion |
|
Perpetual Ltd
AU:PPT
|
Australia | AU$1.74 Billion |
|
Corporativo GBM S.A.B. de C.V
MX:GBMO
|
Mexico | MX$65.10 Billion |
Liability Composition Analysis (2000–2025)
This chart breaks down Innoviva Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Innoviva Inc balance sheet quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 16.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.38 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Innoviva Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Innoviva Inc (2000–2025)
The table below shows the annual total liabilities of Innoviva Inc from 2000 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $462.32 Million | -24.20% |
| 2024-12-31 | $609.90 Million | +7.27% |
| 2023-12-31 | $568.55 Million | -14.59% |
| 2022-12-31 | $665.71 Million | +66.24% |
| 2021-12-31 | $400.46 Million | +2.23% |
| 2020-12-31 | $391.73 Million | +2.36% |
| 2019-12-31 | $382.71 Million | -1.65% |
| 2018-12-31 | $389.14 Million | -36.21% |
| 2017-12-31 | $610.04 Million | -16.66% |
| 2016-12-31 | $731.99 Million | -2.61% |
| 2015-12-31 | $751.58 Million | +0.88% |
| 2014-12-31 | $745.00 Million | +94.96% |
| 2013-12-31 | $382.13 Million | +78.94% |
| 2012-12-31 | $213.55 Million | -38.25% |
| 2011-12-31 | $345.83 Million | -2.20% |
| 2010-12-31 | $353.62 Million | -4.53% |
| 2009-12-31 | $370.39 Million | -0.19% |
| 2008-12-31 | $371.11 Million | +62.59% |
| 2007-12-31 | $228.25 Million | +14.63% |
| 2006-12-31 | $199.11 Million | +20.49% |
| 2005-12-31 | $165.25 Million | +72.76% |
| 2004-12-31 | $95.66 Million | -77.49% |
| 2003-12-31 | $425.01 Million | +0.09% |
| 2002-12-31 | $424.65 Million | +1773.59% |
| 2000-12-31 | $22.66 Million | -- |
About Innoviva Inc
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The com… Read more